FLGT
Fulgent Genetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$20.10
+1.46%Year over year
Reported trailing growth
- Revenue
- +6.8%
- EBITDA
- -48.5%
- EBIT
- -65.2%
- EPS
- -70.9%
- Free cash flow
- -73.1%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +14.5%
- EBITDA
- +71.7%
- EPS
- +38.7%
Three-year CAGR
- Revenue
- -19.5%
- EBITDA
- -70.6%
- EBIT
- -23.2%
- Net income
- -41.7%
- EPS
- -39.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026